<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744638</url>
  </required_header>
  <id_info>
    <org_study_id>DF-WCT-2014</org_study_id>
    <nct_id>NCT02744638</nct_id>
  </id_info>
  <brief_title>Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis</brief_title>
  <official_title>Double-blind, Randomized, Controlled Trial to Evaluate the Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains (L. Crispatus, L. Gasseri, L. Rhamnosus, L. Jensenii) on Bacterial Vaginosis (BV) in Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center Kiel GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairyfem R&amp;D GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Natural Resources and Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center Kiel GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is, to investigate, whether the consumption of a probiotic yoghurt&#xD;
      containing 4 probiotic strains naturally colonizing the vagina (L. crispatus, L. gasseri, L.&#xD;
      rhamnosus, L. jensenii) has an influence on the comfort of adult women with BV after and 3&#xD;
      weeks following a standard antibiotic treatment with metronidazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female volunteers aged ≥18 years with stable menstrual cycle or postmenopausal women&#xD;
      presenting with a newly diagnosed bacterial vaginosis based on Amsel criteria, complying with&#xD;
      a standard oral antibiotic treatment (Metronidazol (Arilin®) 7 days 2x500mg), willing to&#xD;
      consume for 4 weeks the study product two times daily, complying with the dietary&#xD;
      restrictions (s. a.) and complying with the other inclusion and exclusion criteria will be&#xD;
      enrolled in the study. After enrollment subjects will be randomly and evenly assigned to one&#xD;
      of the two test groups verum and placebo.The study population will be recruited in a&#xD;
      screening examination (G1) by gynaecologists from Kiel area. This screening examination&#xD;
      (routine examination) by gynaecologist is used to provide the diagnosis BV. After enrolment&#xD;
      subjects will be randomly assigned to one of the two test groups verum (n=108) and placebo&#xD;
      (n=108).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of BV-free woman</measure>
    <time_frame>4 weeks</time_frame>
    <description>The rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Nugent score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration (G2 - G1) of Nugent Score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alteration (G2 - G1) of symptom score based on Amsel criteria (Yes=1; No=0) and 3 (Yes=1; No=0) resulting in a score ranging from 0 to 2</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>probiotic yoghurt &amp; Arilin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemically acidified milk &amp; Arilin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>probiotic yoghurt</intervention_name>
    <description>verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.</description>
    <arm_group_label>probiotic yoghurt &amp; Arilin</arm_group_label>
    <other_name>verum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chemically acidified milk</intervention_name>
    <description>Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).</description>
    <arm_group_label>chemically acidified milk &amp; Arilin</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arilin</intervention_name>
    <description>2 tablets Arilin 500mg for 7 days</description>
    <arm_group_label>chemically acidified milk &amp; Arilin</arm_group_label>
    <arm_group_label>probiotic yoghurt &amp; Arilin</arm_group_label>
    <other_name>Metronidazol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be enrolled, the following criteria have to be fulfilled:&#xD;
&#xD;
          1. Woman aged ≥ 18 years with stable menstrual cycle or postmenopausal women&#xD;
&#xD;
          2. Newly diagnosed bacterial vaginosis based on Amsel criteria&#xD;
&#xD;
          3. Complies with a standard oral antibiotic treatment with Metronidazol for 7 days, 2 x&#xD;
             500mg/day)&#xD;
&#xD;
          4. Willing to consume for 4 weeks the study product two times daily&#xD;
&#xD;
          5. Willingness to abstain from food and supplements containing probiotics, prebiotics and&#xD;
             other fermented products as well as dietary supplements&#xD;
&#xD;
          6. Not in menses at the time of the first examination at the gynaecologist (G1)&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects currently enrolled in another clinical study.&#xD;
&#xD;
          2. Subjects having finished another clinical study within the last 4 weeks before&#xD;
             inclusion.&#xD;
&#xD;
          3. Infection caused by Chlamydia trachomatis&#xD;
&#xD;
          4. Infection caused by Neisseria gonorrhoea&#xD;
&#xD;
          5. Infection caused by Trichomonas vaginalis&#xD;
&#xD;
          6. Infection caused by Candida albicans or other mycosis&#xD;
&#xD;
          7. Leucocytes present in the vaginal smear&#xD;
&#xD;
          8. PAP-testing ≥ 3 (anamnestically)&#xD;
&#xD;
          9. Vulvovaginal inflammation as macroscopically identified by the gynaecologist&#xD;
&#xD;
         10. Dyspareunia&#xD;
&#xD;
         11. Pregnancy and breastfeeding&#xD;
&#xD;
         12. Chemically based contraceptives (e.g. suppositories, salves, foam, gel)&#xD;
&#xD;
         13. Irregular cycles (e.g. polymenorrhoea, metrorrhagia)&#xD;
&#xD;
         14. Dysuria&#xD;
&#xD;
         15. Infection of the urinary tract&#xD;
&#xD;
         16. Chronic or sporadic abdominal pain with exception of dysmenorrhoea&#xD;
&#xD;
         17. Any ano-rectal infection, disease, surgery in the medical history or current&#xD;
&#xD;
         18. Anus praeter&#xD;
&#xD;
         19. Hypersensitivity, allergy or idiosyncratic reaction to metronidazole or any similar&#xD;
             active substances.&#xD;
&#xD;
         20. Hypersensitivity, allergy or idiosyncratic reaction to any component of the yoghurt&#xD;
             (e.g. lactose intolerance, allergy against milk protein)&#xD;
&#xD;
         21. Any disease or condition which might compromise significantly the hematopoietic,&#xD;
             renal, endocrine, pulmonary, hepatic, gastrointestinal, cardiovascular, immunological,&#xD;
             central nervous, dermatological or any other body system with the exception of the&#xD;
             conditions defined by the inclusion criteria.&#xD;
&#xD;
         22. History of hepatitis B and C&#xD;
&#xD;
         23. History of HIV infection&#xD;
&#xD;
         24. Regular medical treatment including OTC, which may have impact on the study aims (e.g.&#xD;
             probiotics, antibiotic drugs, laxatives etc.)&#xD;
&#xD;
         25. Major cognitive or psychiatric disorders&#xD;
&#xD;
         26. Subjects who are scheduled to undergo hospitalization during the study period&#xD;
&#xD;
         27. Eating disorders (e.g. anorexia, bulimia) or special diets (e.g. vegan, vegetarian)&#xD;
&#xD;
         28. Present drug abuse or alcoholism, reformed alcoholic&#xD;
&#xD;
         29. Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRC Clinical Research Center Kiel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRC Clinical Research Center Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial vaginosis</keyword>
  <keyword>probiotics</keyword>
  <keyword>Amsel Score</keyword>
  <keyword>Nugent Score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

